Related Experiment Videos

The effectiveness of beta-blockers in women with congestive heart failure

Golyar Keyhan1, Shun-Fu Chen, Louise Pilote

  • 1Division of Clinical Epidemiology, The Research Institute of the McGill University Health Center, 1650 Cedar Avenue, Rm L10-421, Montreal, Quebec, Canada, H3G 1A4.

Journal of General Internal Medicine
|May 1, 2007
PubMed

Insights

Beta-blockers improve survival in patients with congestive heart failure (CHF). This study found similar survival benefits for women and men using beta-blockers for CHF, highlighting the need for more research in women.

Area of Science:

  • Cardiology
  • Pharmacology
  • Geriatric Medicine

Background:

  • Beta-blockers are established treatments for congestive heart failure (CHF).
  • Limited research exists on beta-blocker efficacy specifically in female CHF patients.
  • This study addresses the gap in understanding treatment effects in women.

Purpose of the Study:

  • To evaluate the effectiveness of beta-blockers in improving survival for women with CHF.
  • To compare the survival benefits of beta-blockers between men and women diagnosed with CHF.

Main Methods:

  • Retrospective cohort study utilizing administrative healthcare databases in Quebec, Canada.
  • Included over 27,000 patients aged 65+ discharged with CHF between 1998 and 2003.
  • Compared survival outcomes between beta-blocker users and non-users, with follow-up data until March 2004.

Main Results:

  • Beta-blocker use demonstrated a significant survival benefit in both women (HR 0.79) and men (HR 0.76).
  • Sensitivity analyses confirmed similar survival advantages across sexes after adjusting for selection bias.
  • Women were older and had more hypertension; men had higher rates of myocardial infarction.

Conclusions:

  • Beta-blockers appear to offer comparable survival improvements for women and men with CHF.
  • Further clinical trials with substantial female participation are essential to confirm these findings.
  • Current evidence suggests beta-blockers are beneficial for women with congestive heart failure.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...